US Stock MarketDetailed Quotes

ELTX Elicio Therapeutics

Watchlist
  • 5.050
  • -0.100-1.94%
Close Dec 18 16:00 ET
54.50MMarket Cap-1.16P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    Dec 12 06:13
    Update
    $Elicio Therapeutics (ELTX.US)$ Elicio Therapeutics Presents Updated Results From ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
    GlobeNewswire· 12 mins ago
    Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
    Strong correlation observed between mRFS and strength of T cell response
    Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025
    Jaguar8
    Jaguar8
    Dec 12 06:04
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
    Thursday, 12th December at 7:00 am
    Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
    Strong correlation observed between mRFS and strength of T cell response
    Event-driven interim analysis from randomized Phase 2 trial expected in H1 20...
    Jaguar8
    Jaguar8
    Dec 3 06:05
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
    Tuesday, 3rd December at 7:00 am
    BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the completion of enrollment in the Phase 2 AMPLIFY-7P study (NCT05726864). The randomized Phase 2 st...
    Jaguar8
    Jaguar8
    Nov 7 15:06
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
    Elicio Therapeutics presented updated preliminary results from the AMPLIFY-7P Phase 1 clinical trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumors. Key findings show mKRAS-specific T cell responses in all evaluable patients, with the 4.9 mg dose group showing 12-fold higher ...
    Jaguar8
    Jaguar8
    Oct 31 07:34
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
    Elicio Therapeutics (Nasdaq: ELTX) announced two upcoming presentations in November 2024. At the SITC 39th Annual Meeting (Nov 6-10), they will present updated T cell and Disease-Free Survival data from the AMPLIFY-7P Phase 1 trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumor...
Read more
Trending US Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Symbol Mini Chart % Chg
Dorian LPG
LPG
+1.66%
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
0.00%
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
0.00%
eBay
EBAY
-0.19%
Lantheus
LNTH
-1.63%

Unlock the Full List